Recent Advances

CITN and ION operate with a singular strategic focus on testing promising immunotherapy agents and advancing them into the clinic to treat patients. Our trials have been the basis for groundbreaking therapies that have changed the standards of care for two cancers: Merkel cell carcinoma (a rare skin cancer) and T-cell lymphoma (the most common blood cancer). Immunotherapy agents are now recommended for the treatment of patients with these diseases.

black cancer ribbon representing merkel cell carcinoma

Treating Merkel Cell Carcinoma

green cancer ribbon representing t-cell lymphoma

Treating T-cell Lymphoma

disease ribbon representing HIV

Clinical Trials for People with HIV

yellow disease ribbon representing clinical trials for children

Clinical Trials for Children

Treating Merkel Cell Carcinoma

Immunotherapy in the form of a class of compounds known as check-point inhibitors are now recommended to treat Merkel cell carcinoma, a rare form of skin cancer. It has been effective in some people with advanced disease who have not responded to other treatments. For example, twenty-three patients had at least one documented radiologic or clinical assessment of response. Fifteen of 23 evaluable patients (65%) responded (4 complete responses and 11 partial responses). Two additional patients had stable disease and 6 had progressive disease as best response.

Read Abstract
View Study Summary

Media Contact

The Cancer Immunotherapy Trials Network (CITN) and Immune-Oncology Network (ION) strive to make promising experimental immunotherapies broadly available to people with cancer. The goal of immunotherapy is to unleash a patient’s own immune system, enabling it to fight cancer.

We focus on testing novel agents in innovative clinical trials. Our trials are designed to provide critical data that helps speed potential therapies from experimental stages to wide-spread use treating patients with cancer.

We employ the collective expertise of top academic immunologists to design and conduct cancer trials with the most promising immunotherapy agents prioritized for high potential in treating cancer, in collaboration with the National Cancer Institute, foundation, and industry partners.